Surgery and inhibitor development in hemophilia A: A systematic review

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 10, 2011, Pages 1948-1958

  Eckhardt, C L ^a,b   Van der Bom, J G ^c   Van Der Naald, M ^b   Peters, M ^a   Kamphuisen, P W ^b   Fijnvandraat, K ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibody; Hemophilia A; Intensive FVIII exposure; Risk factor; Surgery; Systematic review

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ARTICLE; BLEEDING; CONTINUOUS INFUSION; DISEASE SEVERITY; EMERGENCY WARD; FOLLOW UP; GROUPS BY AGE; HEMOPHILIA A; HUMAN; INTENSIVE CARE; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURGICAL RISK; SYSTEMATIC REVIEW;

BLOOD LOSS, SURGICAL; FACTOR VIII; HEMOPHILIA A; HUMANS; RISK ASSESSMENT; SERINE PROTEINASE INHIBITORS;

EID: 80053395694     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04467.x     Document Type: Article

References (45)

1. Eckhardt CL, van der Bom JG, van der Naald M, Peters M, Kamphuisen PW, Fijnvandraat K. Surgery as a risk factor for inhibitor development in haemophilia A: a systematic review. Haemophilia 2010; Conference: Abstract 17P30.
2. Darby SC, Keeling DM, Spooner RJ, Wan KS, Giangrande PL, Collins PW, Hill FG, Hay CR. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
3. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
4. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
5. Coppola A, Santoro C, Tagliaferri A, Franchini M, Di Minno G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia 2010; 16 (Suppl. 1): 13-9.
6. Dasgupta S, Navarrete AM, Delignat S, Wootla B, Andre S, Nagaraja V, Lacroix-Desmazes S, Kaveri SV. Immune response against therapeutic factor VIII in hemophilia A patients - a survey of probable risk factors. Immunol Lett 2007; 110: 23-8.
7. Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009; 35: 723-34.
8. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5.
9. Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A, Holme PA, Karafoulidou A, Lopez-Fernandez MF, Reipert BM, Rocino A, Schiavoni M, von Depka M, Windyga J, Fijnvandraat K. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010; 16: 747-66.
10. von Auer CH, Oldenburg J, von Depka M, Escuriola-Ettinghausen C, Kurnik K, Lenk H, Scharrer I. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 2005; 1051: 498-505.
11. Hermans C, Altisent C, Batorova A, Chambost H, De Moerloose P, Karafoulidou A, Klamroth R, Richards M, White B, Dolan G. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009; 15: 639-58.
12. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
13. Laupacis A, Wells G, Richardson WS, Tugwell P. Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA 1994; 272: 234-7.
14. Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet 2002; 359: 341-5.
15. Sharathkumar A, Lillicrap D, Blanchette VS, Kern M, Leggo J, Stain AM, Brooker L, Carcao MD. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
16. Maclean PS, Richards M, Williams M, Collins P, Liesner R, Keeling DM, Yee T, Will AM, Young D, Chalmers EA. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 2011; 17: 282-7.
17. Aznar JA, Magallon M, Querol F, Gorina E, Tusell JM. The orthopaedic status of severe haemophiliacs in Spain. Haemophilia 2000; 6: 170-6.
18. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38: 44-51.
19. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38 (Suppl. 4): 52-9.
20. Eckhardt CL, Menke LA, van Ommen CH, van der Lee JH, Geskus RB, Kamphuisen PW, Peters M, Fijnvandraat K. Intensive peri-operative use of factor VIII and the Arg593 -> Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009; 7: 930-7.
21. Feldman BMP. Tailored prophylaxis in severe hemophilia A: interim results from the first 5years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
22. Gascoigne EW, Dash CH, Harman C, Wilmot D. A retrospective survey on the safety of Replenate, a high-purity factor VIII concentrate. Pharmacoepidemiol Drug Saf 2004; 13: 243-52.
23. Ghosh K, Shetty S, Kulkarni B, Nair S, Pawar A, Khare A, Baindur S, Mohanty D. Development of inhibitors in patients with haemophilia from India. Haemophilia 2001; 7: 273-8.
24. Giangrande PL; KOGENATE Bayer Study Group. Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia 2002; 8 (Suppl. 2): 19-22.
25. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5: 1383-90.
26. Gouw SC, van der Bom JG, van den Berg MH. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
27. Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM, The E. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. Haemophilia 2006; 12: 128-32.
28. Houissa B, Mliki ML, Abdelkafi S, Bouslama M, Zaier M, Mahjoub T, Kortas M, Ghachem L, Yacoub S. Treatment of haemophilia A in Tunisia: efficacy and inhibitor study. Hamostaseologie 2003; 23: 144-8.
29. Knobe KE, Sjörin E, Tengborn LI, Petrini P, Ljung RC. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. Acta Paediatr 2002; 91: 910-4.
30. Kreuz W, Gill JC, Rothschild C, Manco-Johnson MJ, Lusher JM, Kellermann E, Gorina E, Larson PJ. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005; 93: 457-67.
31. Mancuso ME, Mannucci PM, Sartori A, Agliardi A, Santagostino E. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters. Br J Haematol 2008; 141: 689-95.
32. Mauser-Bunschoten EP, Posthouwer D, Fischer K, van den Berg HM. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10years of follow-up. Haemophilia 2007; 13: 697-700.
33. Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J, Ingerslev J, Lambert T, Maas-Enriquez M, Gorina E; KOGENATE Bayer European PMS Study Group. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2008; 99: 52-8.
34. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, Messina M, Mannucci PM. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-7.
35. White GC, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost 1997; 77: 660-7.
36. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G III, Lee M. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
37. Kempton CL, Soucie JM, Miller CH, Hooper C, Escobar MA, Cohen AJ, Key NS, Thompson AR, Abshire TC. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost 2010; 8: 2224-31.
38. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P. Prophylaxis vs. episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
39. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2006; 2: CD003429.
40. Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost 2010; 8: 421-32.
41. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia 2000; 6 (Suppl. 1): 60-7.
42. d'Oiron R, Pipe SW, Jacquemin M. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia 2008; 14 (Suppl. 3): 138-46.
43. Kaplan J, Genyea C, Secord E. Factor VIII inhibitors. Potential for prevention of inhibitor formation by immune tolerance. Semin Thromb Hemost 2000; 26: 173-8.
44. Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol 2010; 148: 522-33.
45. Mauser-Bunschoten EP, Fransen van de Putte DE, Schutgens RE. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 2009; 15: 853-63.